Back in 2018 I wrote an article about the new Libre 2. Finally (as of yesterday) Abbott has got the Libre 2 approved with the TGA for use in Australia.
All we know about the rollout and availability of the product is a statement by Abbott that it will be made available “over the coming months” and will be priced the same as the current Libre (1). That is, $92.50 for a 14-day sensor.
At this point I don’t expect to see the Libre 2 added to the NDSS CGM Subsidy scheme until the next update (at the same time I would expect the Dexcom G6 to be added for more than just t:slim Basal-IQ users).
What’s the difference?
To briefly recap, the Libre 2 can be used in the same way as the Libre 1. With both a handheld Reader device (which is blue for the Libre 2) and with a phone app.
While their designed use is for you to scan the sensor manually to get the readings (as with the current product) the sensor actually transmits the current BG value to the app/Reader every minute, and this is used to implement alarms.
This is one of the big things that has previously separated FGM – “Flash Glucose Monitoring” from CGM (Continuous Glucose Monitoring) and will make a lot of people happy.
There have been other important updates to the product too, such as:
- A new algorithm that seems to do a better job of calculating BG values.
- Per-sensor factory calibrations (instead of per-batch) which further improves the accuracy.
I’m excited to eventually get my hands on one and see how it goes!